To

Date: 10.11.2026

The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001

Dear Sir/ Madam,

Unit: Oxygenta Pharmaceutical Limited (Scrip: 524636)

Sub: Outcome of Board Meeting

With reference to the subject cited this is to inform the Exchange that the Board of Directors of **Oxygenta Pharmaceutical Limited,** at its Meeting held on Tuesday, 10th November, 2026, at 12:30 p.m. at the corporate office of the Company, considered and approved the following:

1. Un-audited Financial Results for the quarter and half year ended 30.09.2026. **(Attached)**
2. Limited Review Report for the quarter ended 30.09.2026. **(Attached)**

The Meeting concluded at 4:00 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Oxygenta Pharmaceutical Limited

Mamilla Balasubba Reddy
Digitally signed by Mamilla Balasubba Reddy
Date: 2026.11.10 16:15:03 +05'30'

Balasubba Reddy Mamilla
Whole-time Director
(DIN: 01998852)

OXYGENTA PHARMACEUTICAL LIMITED

CIN : L24110TG1990PLC012038

Regd Office: Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy Dist, Telangana State

Corp Office: Level-1 Plot No B1 and B2, IDA Gandhi Nagar, Balanagar Township Hyderabad

Website: www.oxygentapharma.com, Email Ids: cs@oxygentapharma.com, Phone Number: 040- 23355938

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER 2026

(Rupees in Lakhs except for EPS)

S. No	Particulars	Quarter Ended			Half Year Ended		YEAR ENDED
		30/09/2026	30/06/2026	30/09/2025	30/09/2026	30/09/2025	31/03/2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**Revenue**						
	(a) Revenue from operations	3,349.39	3,699.69	1,430.23	7,049.09	2,943.69	11,298.19
	(b) Other Income	2.02	2.33	-5.62	4.35	11.29	28.58
	Total revenue	**3,351.41**	**3,702.02**	**1,424.61**	**7,053.44**	**2,954.99**	**11,326.77**
2	**Expenses**						
	(a) Cost of materials consumed	2,438.42	2,340.08	1,696.51	4,778.50	3,262.39	11,033.85
	(b) Changes in inventories of finished goods, work- in-progress and stock-in-tra	240.44	684.48	(452.80)	924.92	(523.14)	(820.30)
	(c) Employee benefit expense	196.62	195.33	203.47	391.96	403.66	764.49
	(d) Finance Costs	273.02	245.90	94.96	518.92	157.80	477.69
	(e) Depreciation and amortisation expense	71.38	61.84	85.71	133.22	170.44	232.26
	(f) Other expenses	471.08	425.10	440.54	896.19	941.24	1,856.81
	Total expenses	**3,690.96**	**3,952.75**	**2,068.39**	**7,643.71**	**4,412.39**	**13,544.79**
3	**Profit before exceptional items and tax(1-2)**	**(339.54)**	**(250.73)**	**(643.78)**	**(590.27)**	**(1,457.40)**	**(2,218.02)**
4	**Exceptional Income/(expenses)**	-	-	-	-	(1.39)	-
5	**Profit / (Loss) before tax (3+ 4)**	**(339.54)**	**(250.73)**	**(643.78)**	**(590.27)**	**(1,458.79)**	**(2,218.02)**
6	**Tax expense /(credit)**						-
	a)Current Tax	-	-		-		-
	b)Deferred Tax	(66.01)	(40.36)	(150.74)	(106.37)	(354.93)	(460.86)
	Prior period Income tax adjustment	-			-		-
7	**Net Profit / (Loss) for the period (5+ 6)**	**(273.53)**	**(210.37)**	**(493.04)**	**(483.90)**	**(1,103.87)**	**(1,757.17)**
8	**Other Comprehensive Income**						
	(a) (i) Items that will not be reclassified to profit or loss	-			-		70.99
	(ii) Tax on items that will not be reclassified to profit or loss	-			-		(18.46)
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-		-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-		-
	Total Other Comprehensive Income/(loss)	-	-	-	-		**52.54**
9	**Total Comprehensive Income(7+8)**	**(273.53)**	**(210.37)**	**(493.04)**	**(483.90)**	**(1,103.87)**	**(1,704.63)**
10	**Paid-up equity share capital (face value Rs. 10/- each)**	3,698.35	3,698.35	3,698.35	3,698.35	3,698.35	3,698.35
11	**Earnings per equity share (of Rs.10/- each) (not annualised):**						
	(a) Basic	**(0.74)**	**(0.57)**	**(1.33)**	**(1.31)**	**(2.98)**	**(4.75)**
	(b) Diluted	**(0.74)**	**(0.57)**	**(1.33)**	**(1.31)**	**(2.98)**	**(4.75)**

NOTES:

1. The financial results of the company have been prepared in accordance with Indian Accouting Standards (Ind AS) notified under the companies (Indian Accouting standards) Rules, 2015 as amended by the companies (Indian Accouting standards) (Amendment) rules,2016.
2. The above Financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 10th Nov 2026 at Corporate office, Level-1 Plot No B1 and B2, IDA Gandhi Nagar, Balanagar Township, Hyderabad, Rangareddy, Telangana, India, 500037
3. The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the board meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015
4. Total Revenue for the current quarter reported Rs. 3349.39 Lakhs compared to Rs. 1430.23 lakhs for the corresponding quarter of the previous year.
5. The Loss before tax for the current quarter is Rs.339.54 Lakhs compared to Loss Before tax of Rs.643.78 Lakhs for the corresponding quarter of the previous year.
6. The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made.
7. The results for the quarter ended 30th September 2026 are also available on the bomabay stock exchange website, the National Stock exchange website and on the Company's website.
8. The Company is actively working to complete the identification of its MSME creditors, though a few gaps remain in this process. To facilitate accurate identification, we have requested all suppliers to submit self-declaration forms confirming their MSME status. The Company is currently in the process of collecting these declarations from suppliers to enhance accuracy in reporting.

For and on behalf of the Board of Directors of,
OXYGENTA PHARMACEUTICAL LIMITED

Balasubba Reddy Mamilla
Whole Time Director
DIN: 01998852

Date: 10/11/2026
Place: Hyderabad

OXYGENTA PHARMACEUTICAL LIMITED
CIN: L24110TG1990PLC012038
Balance Sheet as at September 30,2026

(All amounts are in INR Lakhs, unless otherwise stated)

Particulars	Note	As at September 30, 2026	As at March 31,2026
I. ASSETS			
Non-current assets			
(a) Property, plant and equipment	3	4,927.53	4,759.90
(b) Capital work in progress		106.52	-
(c) Financial assets			
(i) Investments	4	47.40	47.40
(ii) Trade Receivables	5	-	176.86
(iii) Other financial assets	6	149.23	100.19
(d) Deferred tax assets (net)	7	1,847.11	1,740.74
Total non-current assets		**7,077.79**	**6,825.08**
Current assets			
Inventories	8	1,845.13	2,942.11
(a) Financial assets			
(i) Trade receivables	5	2,017.50	1,002.78
(ii) Cash and cash equivalents	9	128.06	41.90
(iii) Bank balances other than Cash and cash equivalents		176.63	173.00
(b) Other current assets	10	521.93	983.18
Total Current Assets		**4,689.26**	**5,142.98**
TOTAL ASSETS		**11,767.05**	**11,968.06**
II. EQUITY AND LIABILITIES			
Equity			
(a) Equity share capital	11	3,698.35	3,698.35
(b) Other equity	12	(8,409.37)	(7,967.03)
Total equity		**(4,711.02)**	**(4,268.68)**
Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	13A	7,787.59	7,528.60
(b) Provisions	14A	111.91	98.44
Total non-current Liabilities		**7,899.50**	**7,627.04**
Current liabilities			
(a) Financial liabilities			
(i) Borrowings	13B	3,646.12	3,428.08
(ii) Trade payables			
- Total outstanding dues of micro and small enterprises	15	559.44	357.51
- Total outstanding dues of creditors other than micro and small enterprises		4,132.48	4,519.39
(iii) Other Financial liabilities	16	170.56	166.46
(b) Other current liabilities	17	63.84	112.74
(c) Provisions	14B	6.13	25.52
Total current liabilities		**8,578.56**	**8,609.70**
TOTAL EQUITY AND LIABILITIES		**11,767.05**	**11,968.06**
Material Accounting Policies	2		
Notes forming part of Financial statements	1-60		

For and on behalf of the Board of Directors of
OXYGENTA PHARMACEUTICAL LIMITED
CIN: L24110TG1990PLC012038

OXYGENTA PHARMACEUTICAL LIMITED Hyderabad

Balasubba Reddy Mamilla
Whole Time Director
DIN: 01998852

Place: Hyderabad
Date: 10/11/2026

OXYGENTA PHARMACEUTICAL LIMITED

CIN: L24110TG1990PLC012038

Statement of Cash Flows for the Period ended September 30, 2026

(All amounts are in INR Lakhs, except for share data and where otherwise stated)

Particulars	For the Period ended September 30, 2026	For the Year ended March 31, 2026
I CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	(590.27)	(2,218.02)
Adjustments for:		
Depreciation and amortisation expenses	133.22	232.26
Finance costs	518.92	477.69
Interest income	(4.04)	(7.97)
Acturial Gain/(Loss)- OCI	-	28.53
Provisions	20.52	72.33
Operating profit before working capital changes	**78.36**	**(1,415.18)**
Working capital changes:		
(Increase)/Decrease in Trade receivables	(837.86)	(561.53)
(Increase) in Other financial assets	(3.39)	(10.21)
Decrease in Other current assets	461.25	(478.07)
(Increase)/Decrease in Inventories	1,096.98	(890.81)
(Decrease) in Trade payables	(184.98)	1,897.52
Increase/(Decrease) in Other current liabilities	(48.91)	(1,254.01)
Increase/(Decrease) in Provisions	(26.43)	(78.89)
Cash generated from operations	**535.02**	**(2,791.19)**
Income taxes received/(paid)		15.90
Net cash generated from operating activities	**535.02**	**(2,775.30)**
II CASH FLOW FROM INVESTING ACTIVITIES		
Payment for property plant and equipment and CWIP	(407.38)	(1,285.69)
Proceeds from sale of property plant and equipment and CWIP	-	-
Interest received on fixed deposits	4.04	7.97
Movement in other bank balances and bank deposits with maturity period of more than three months	(3.63)	(160.99)
Net cash generated from/(used in) investing activities	**(406.97)**	**(1,438.71)**
III CASH FLOW FROM FINANCING ACTIVITIES		
Interest paid	(465.47)	(477.69)
Proceeds from issuing shares	-	
Proceeds from issuing other equity instruments	-	-
Increase/(decrease) from Long term borrowings	205.54	5,376.36
Increase/(decrease) from Short term borrowings	218.04	(642.92)
Net cash generated from/(used in) financing activities	**(41.89)**	**4,255.74**
IV Net increase in cash and cash equivalents	86.16	41.73
Cash and cash equivalents at the beginning of the year	41.90	0.17
Cash and cash equivalents at the end of the year	**128.06**	**41.90**


The above standalone statement of cash flow from operating activities has been prepared under the "Indirect method" as set out in IND AS-7 "Statement of cash flows".

Material Accounting Policies	2
Notes forming part of Financial statements	1-60

For and on behalf of the Board of Directors of

OXYGENTA PHARMACEUTICAL LIMITED

CIN: L24110TG1990PLC012038



Balasubba Reddy Mamilla

Whole Time Director

DIN: 01998852

Place: Hyderabad

Date: 10/11/2026

A.M REDDY & D.R REDDY
Chartered Accountants

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of OXYGENTA PHARMACEUTICAL LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Oxygenta Pharmaceutical Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Oxygenta Pharmaceutical Limited ("the Company") for the quarter ended and Six months ended September 30, 2026 ("the Statement ") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")

2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the statement in accordance with the Standard of Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to

H.O #14/186, Flat 203, Ananth Sai Residency kamalnagar, Anantapur 515 001 |Phone No: 08554-231666 B.O H.No 7-66-229/30/37/38, 4th Floor, Flat No: 402, Gayatri Arcade, Prashanthi Hills, Raidurgam, Gachibowli, Hyderabad 500 032 | Phone No: 040-40077393 Mobile No: 9848032382 Email ID: rkreddy1999#yahoo.com

A.M. REDDY & D.R. REDDY ★ Hyderabad ★ Chartered Accountants

obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit Opinion.

4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A.M REDDY & D.R REDDY
Chartered Accountants
Firms Registration No: 009068S

D. Rama Krishna Reddy
Partner
Membership No. 209211
UDIN: 26209211MHOATG5208
Place: Hyderabad
Date: November 10, 2026

A.M. REDDY & D.R. REDDY ★ Hyderabad ★ Chartered Accountants

H.O #14/186, Flat 203, Ananth Sai Residency kamalnagar, Anantapur 515 001 |Phone No: 08554-231666 B.O H.No 7-66-229/30/37/38, 4th Floor, Flat No: 402, Gayatri Arcade, Prashanthi Hills, Raidurgam, Gachibowli, Hyderabad 500 032 | Phone No: 040-40077393 Mobile No: 9848032382 Email ID: rkreddy1999#yahoo.com